• Guest - w'd love to know what you think about the forum! Take the 2025 Survey »

Abbott Anouncement

DavidGrahamJones

DavidGrahamJones

Well-Known Member
Messages
3,262
Location
Hazlemere
Type of diabetes
Type 2
Treatment type
Other
Dislikes
Newspapers
Just some news I've read today.

They have FDA approval which has had a healthy effect on their share price. Also They have announced that they have secured reimbursement for the Freestyle Libre system in the UK. Available on the NHS from 1st November 2017 (subject to local health economy approval).

I'm trying to understand exactly what that means and what the effect will be for say type I and type II users. The bit in brackets indicates that it will depend on the health authority where we live.
 
DavidGrahamJones said:
Just some news I've read today.

They have FDA approval which has had a healthy effect on their share price. Also They have announced that they have secured reimbursement for the Freestyle Libre system in the UK. Available on the NHS from 1st November 2017 (subject to local health economy approval).

I'm trying to understand exactly what that means and what the effect will be for say type I and type II users. The bit in brackets indicates that it will depend on the health authority where we live.
Click to expand...

Postcode Lottery again?
 
Dear FreeStyle user,

This is a reminder for your invitation by the Department of Health to provide comments regarding the NDSS listing of FreeStyle Libre.

As a FreeStyle user, your opinion is important to this process.

Stakeholder comments will play an important role in the independent Advisory Committee’s deliberations. The Department of Health encourages dissemination of this Stakeholder Consultation to all individuals or parties that you may identify as having an interest.

The consultation process is now open and comments can be submitted until 17 July 2017.
Click to expand...

Abbot Australia are discussing this with the Australian Federal Government, I had several invites from the DOH through Abbot to put my comments up by 17.07.2017.

https://consultations.health.gov.au...-consultation-for-freestyle-libre-flash-gluc/
 
tim2000s said:
you might want to have a read of these:

Libre on prescription:
Click to expand...

Thanks for the links, I hope all type 1s can benefit from this device on prescription. Unfortunately us type IIs will have to whistle as the old expression goes. Using the FS Libre has proven to be so useful for me because when the low carb bit stopped working after 3-4 years I was totally flummoxed. Having a CGM made things a lot clearer, still have questions, still work in progress, but at least I know works well.

I wonder if the increase in sales might have a beneficial effect on the price of the sensors?
 
It would be intesting if someone could create a Type2 self management training couse that used the FS Libre as part of the training and include it in the cost of the couse. The NHS does look at cost/benfit of the taining, so if a provider can PROVE much better longterm results for people taking their couse, they should be able to sell it to more CCGs.
 
DavidGrahamJones said:
I wonder if the increase in sales might have a beneficial effect on the price of the sensors?
Click to expand...

Considering it looks like most CCGs won't push it through this financial year I can't see sales going up by much in the near future...........:(
 
Also someone will have to pay for the builk discounts the CCGs demand and get........
 
slip said:
I can't see sales going up by much in the near future...........:(
Click to expand...
ringi said:
someone will have to pay for the builk discounts the CCGs demand
Click to expand...

I was thinking worldwide sales and more specifically the U.S. It will be interesting to see what the take up will be, although selfishly I'd be more worried about supply if demand increases too much.

Interesting: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=4171514 Does it mean marketing and sales of the Libre was held up because of an allergic reaction?
 
DavidGrahamJones said:
I was thinking worldwide sales and more specifically the U.S
Click to expand...

I'm not certain but I thought the US has a slightly different version? Not sure if I read somewhere their 'version' only lasts 10 days - but then again the FDA may have restricted it use/longevity for some reason (perhaps US skin is more sensitive than the rest of the worlds!). I'm unaware of a sales increase of some company's product help reduce the cost of another product - but hey I'm no business man ;)
 
slip said:
I'm unaware of a sales increase of some company's product help reduce the cost of another product
Click to expand...

I wait with bated breath. LOL Just to see how the prices of a sensor in the U.S. compares with the U.K. Also, whereas here in the U.K. there is a chance that some will get this funded by the NHS, in the U.S. it would probably be an insurance job, but I wouldn't be surprised if they would find a way of not paying.

I'm guessing (a calculated guess) that most users in the U.K. fund themselves, there are many factors governing the price of the sensors, some may have nothing to do with actual cost. Let's see how it pans out with the 2 announcements, availability in the U.S. and supply by the N.H.S.
 
not sure if you know but if you work for Abbott you can by the libre for 'friends and family' for....................£20 (just wondering if that's their 'cost' price!)...........unfortunately even though I'm not that far from one of their sites I don't know anyone who works there and I can't fulfil any of their current vacancies! :p
 
So far, what Abbott have said is that they've had 400,000 users worldwide (ex-US), which can be compared with the estimated 140k by Dexcom in March 2016. At that time they estimated that growth rate was 35%, so that would make Dexcom numbers now around 220k.

Who knows the reality? What we do know is that Abbott's last annual results registered that the Libre had definitely added positively to their bottom line.
 
Libre is a uber of the CGM world with usage growing very fast, as "adfordable good enough" results in greatly increased market size.
 
Back
Top